differentiated thyroid cancer

Can Long-Term Thyroid Cancer Follow-Up Safely Move to Primary Care? Prospective Data Support De-Escalation After Excellent Response

By MedXY 05/26/2026

A prospective cohort study suggests that differentiated thyroid cancer patients with sustained excellent response after at least 5 years of specialist follow-up can be safely transitioned to primary care with very low recurrence risk.

news Oncology Pathology & Lab Medicine/Bệnh học

TSH Stimulation Methods Show Comparable Outcomes in Radioiodine-Avid Metastatic Differentiated Thyroid Cancer

By MedXY 05/16/2026

In radioiodine-avid metastatic differentiated thyroid cancer, rhTSH and mixed rhTSH/thyroid hormone withdrawal preparation produced comparable adjusted outcomes. Prognosis was driven mainly by metastatic burden and age, supporting individualized treatment selection.

Cardiology Diabetes & Endocrinology news OB/GYN & Women's Health

Prolonged TSH Suppression in Postmenopausal Thyroid Cancer Patients Linked to Worse Cardiovascular and Quality-of-Life Outcomes

By MedXY 04/28/2026

Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

By MedXY 08/02/2025

The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.